Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
基石药业(苏州)有限公司 CSTONE PHARMACEUTICALS
{{company.company_channel.channel_name}}
Media Room
Latest
Photos
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Follow :
X
Company Profile
Media Room
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.title}}
loading
The End
Network Errors Please Retry
{{selectname}}
{{showName}}
{{selectall}}
{{option}}
CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib
2020-01-24 14:26
CStone successfully hosted the first U.S. R&D Day in New York
2020-01-24 08:18
CStone successfully hosted the first U.S. R&D Day in New York
2020-01-24 08:03
CStone announces first patient dosed in the Phase III trial of CS1001 in combination with chemotherapy in first-line esophageal squamous cell carcinoma
2020-01-08 13:45
CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia
2019-12-12 14:47
CStone announces enrollment target reached in the global Phase III VOYAGER trial of avapritinib in Chinese patients with third-line GIST
2019-12-11 11:00
CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma
2019-12-10 11:38
CStone appoints seasoned pharmaceutical executive Shirley Zhao as the General Manager for Greater China and Head of Commercial
2019-12-06 18:53
CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib
2019-11-20 11:41
ASH 2019 | CStone's anti-PD-L1 antibody demonstrates a complete response rate of 31.8% in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma
2019-11-07 11:02
ESMO 2019: CStone presents pooled safety data from the Phase 1b trial of CS1001, demonstrating promising overall safety and tolerability
2019-09-30 18:29
2019 CSCO| CStone announces promising ORR, anti-tumor activity and safety data with its anti-PD-L1 antibody CS1001 in MSI-H/dMMR solid tumors
2019-09-22 14:22
2019 CSCO | CStone announces preliminary results from Phase I trial of CS1002 demonstrating characteristics comparable to ipilimumab
2019-09-22 13:39
2019 CSCO | CStone releases preliminary results from the Phase Ia trial of CS1003 in Chinese patients with advanced tumors
2019-09-21 00:26
2019 CSCO | CStone announces promising trial data on its anti-PD-L1 antibody in esophageal squamous cell carcinoma with an ORR of 77.8%
2019-09-19 23:48
CStone announces first patient dosed in China for Phase I/II registrational bridging trial of avapritinib in advanced GIST
2019-08-26 11:21
CStone announces data from trials of CS1001, CS1002 and CS1003 to be released for the first time at 2019 CSCO Annual Meeting
2019-08-23 11:26
CStone completes registration filing for the Phase I trial of CDK4/6 inhibitor CS3002 in Australia and will soon initiate the study
2019-08-23 11:20
CStone submits an abstract on CS1001-201 trial to 2019 ASH Annual Meeting
2019-08-20 10:18
Abstract on CStone's CS1001-101 trial accepted for poster presentation at ESMO 2019 Annual Congress
2019-08-19 13:50
1
3
4
5
6
7